Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATR04-484 · 1 trial · 1 indication
Treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| ATR04-484 | EXPERIMENTAL | Topically applied ATR04-484 |
| Vehicle | PLACEBO_COMPARATOR | Topically applied vehicle |
| Name | Type | Description |
|---|---|---|
| ATR04-484 | DRUG | ATR04-484 is a recombinant live biotherapeutic product (rLBP) containing the engineered S. epidermidis strain SE484 in an ointment formulation for topical use |
| Vehicle | DRUG | Topically applied vehicle. |
Inclusion Criteria: * Adults ≥18 years of age * Has Grade 2 or 3 non-infected moderate to severe EGFRi-related dermal toxicity affecting the face (the neck, chest, back and other areas may also be affected) Exclusion Criteria: * Significant skin disease other than EGFRi-related dermal toxicity * ...
ATR04-484 is an investigational small molecule being developed for the treatment of EGFR inhibitor-associated rash, a dermatologic condition that can occur in patients receiving EGFR inhibitor therapy. It is currently in Phase 1 clinical development.
ATR04-484 targets EGFR, the epidermal growth factor receptor. By targeting this protein, the drug is designed to address EGFR inhibitor-associated rash, a dermatologic toxicity linked to EGFR pathway activity.
ATR04-484 is being developed by Azitra Inc, a biopharmaceutical company. Azitra's stock is traded under the ticker symbol AZTR on the stock market.
ATR04-484 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug has received Fast Track designation from the FDA.
ATR04-484 is being evaluated in a Phase 1 clinical trial with the identifier NCT06830863. This randomized, double-blind, placebo-controlled study is recruiting 32 participants in the United States to evaluate the drug for EGFR inhibitor-associated rash.
No, ATR04-484 is a distinct investigational drug. It is not known to be the same as any other approved or investigational medication. It is being studied specifically for its potential to treat EGFR inhibitor-associated rash.